Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2010, Article ID 698594, 6 pages
http://dx.doi.org/10.1155/2010/698594
Review Article

Bortezomib in Kidney Transplantation

1Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
2Division of Nephrology, Baylor College of Medicine, Houston, TX 77030, USA
3Department of Medicine, The Kidney Institute and The Methodist Hospital, Houston, TX 77030, USA
4Division of Nephrology, The Kidney Institute and The Methodist Hospital, Houston, TX 77030, USA
5Department of Surgery, The Methodist Hospital, Weill Cornell University, Houston, TX 77030, USA
6Department of Pharmacy, The Methodist Hospital, Weill Cornell University, Houston, TX 77030, USA

Received 27 July 2010; Accepted 9 September 2010

Academic Editor: H. Kreis

Copyright © 2010 Rajeev Raghavan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Although current therapies for pretransplant desensitization and treatment of antibody-mediated rejection (AMR) have had some success, they do not specifically deplete plasma cells that produce antihuman leukocyte antigen (HLA) antibodies. Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma (a plasma cell neoplasm), induces plasma cell apoptosis. In this paper we review the current body of literature regarding the use of this biological agent in the field of transplantation. Although limited experience with bortezomib may seem to show promise in the realm of transplant recipients desensitization and treatment of AMR, there is also experience that may suggest otherwise. Bortezomib's role in desensitization protocols and treatment of AMR will be defined better as more clinical data and trials become available.